A Legacy Remembered

Dr. Stephen A. Harrison, MD (1969-2024)
A Pioneering Force in Hepatology and Patient Care

The medical and patient communities suffered an immeasurable loss with the untimely passing of Dr. Stephen A. Harrison last year. As a visionary hepatologist, Dr. Harrison dedicated his career to advancing our understanding of liver diseases and developing innovative treatments that have improved countless lives worldwide.

A Distinguished Career in Hepatology

Dr. Harrison established himself as one of the world's foremost authorities on Steatotic liver diseases (MASLD/NAFLD) and  (MASH/NASH). After completing his medical training at the Uniformed Services University of Health Sciences, he served as a physician in the United States Army, rising to the rank of Colonel while simultaneously building his academic career.

His professional journey included pivotal roles as Medical Director of Pinnacle Clinical Research, Visiting Professor at the University of Oxford, and Professor of Medicine at the University of Texas Health Science Center. Throughout his career, Dr. Harrison was at the vanguard of liver disease research, particularly focusing on metabolic dysfunction-associated steatotic liver disease.

Research Contributions to Hepatology

Dr. Harrison's research portfolio was both extensive and transformative. His work as principal investigator in numerous clinical trials helped establish new frontiers in NAFLD/NASH treatment. His commitment to scientific rigor and innovation resulted in over 200 peer-reviewed publications and countless presentations at international conferences.

Some of his most influential research publications include:

  1. REGENERATE Study: Dr. Harrison was a lead author on this landmark phase 3 trial evaluating obeticholic acid for NASH treatment, published in *The New England Journal of Medicine*. This study represented a significant advancement in therapeutic options for a disease without approved pharmacological treatments.
    [https://www.nejm.org/doi/full/10.1056/NEJMoa1808035](https://www.nejm.org/doi/full/10.1056/NEJMoa1808035)]
  2. MAESTRO-NASH: His work on Resmetirom, published in *The Lancet*, demonstrated promising results for treating NASH and liver fibrosis.
    [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01429-5/fulltext]
  3. Hepatic De Novo Lipogenesis in NAFLD: Dr. Harrison's groundbreaking research on lipogenesis mechanisms in *Gastroenterology* helped elucidate key pathophysiological processes.
    [https://www.gastrojournal.org/article/S0016-5085(19)41895-5/fulltext](https://www.gastrojournal.org/article/S0016-5085(19)41895-5/fulltext)]
  4. Non-invasive Assessment of NASH: His work on FibroScan-AST (FAST) score published in *Journal of Hepatology* transformed diagnostic approaches for NASH.
    [https://www.journal-of-hepatology.eu/article/S0168-8278(20)30214-8/fulltext](https://www.journal-of-hepatology.eu/article/S0168-8278(20)30214-8/fulltext)]

Impact Beyond Research

Dr. Harrison's influence extended far beyond his publications. As a founding member of the Liver Forum and a key contributor to the American Association for the Study of Liver Diseases (AASLD) practice guidelines, he helped shape treatment standards worldwide. His ability to translate complex scientific discoveries into practical clinical applications characterized his approach to medicine.

Colleagues remember him not only for his scientific brilliance but also for his generous mentorship. Dr. Harrison nurtured a generation of hepatologists who continue to build upon his legacy. At international conferences, his presentations were consistently standing-room-only events, reflecting the immense respect he commanded within the field.

A Compassionate Clinician

Despite his research achievements, Dr. Harrison never lost sight of what mattered most – his patients. He approached each case with extraordinary empathy, recognizing that behind every liver scan was a person seeking hope. His patient-centered approach informed his research priorities, always focusing on developing treatments that would meaningfully improve our quality of life.

Enduring Legacy

Dr. Harrison's passing leaves an enormous void in the hepatology community, but his legacy endures through his research, the clinical trials he pioneered, and the countless physicians he inspired. The therapeutic pathways he helped identify continue to drive drug development for liver diseases that affect hundreds of millions globally.

The Stephen A. Harrison Research Fund has been established to support early-career investigators pursuing innovative approaches to liver disease treatment, ensuring that his commitment to scientific advancement continues.

The Stephen A. Harrison Patient Advocacy Fellowship Program is a pioneering initiative designed to elevate the role of patient advocates in MASH (Metabolic Dysfunction-Associated Steatohepatitis) and steatotic liver disease research, drug development, and policy discussions.

As we reflect on Dr. Harrison's remarkable life and career, we recognize that his greatest contribution may have been demonstrating how clinical excellence and scientific innovation can combine to transform medicine. In laboratories and clinics worldwide, his influence continues to shape how we understand and treat liver disease.

The medical and patient communities have lost a brilliant mind and compassionate heart, but Dr. Stephen Harrison's vision for improving liver health worldwide remains very much alive in the work of those privileged to follow in his footsteps. If you knew Stephen personally and would like to share that experience with others, we invite you to contribute to our memories page where we are collecting stories from those who knew and loved him.